Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – August 6, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that its SHIR™ CBD Derma Cosmetic product line, has successfully passed safety assessment in accordance with European Union (EU) cosmetic regulation No 1223/2009 and received a EU Cosmetic Product Safety Report for marketing in the European Union.
SHIR™ skincare products combine the benefits of CBD with the most effective ingredients in an innovative formula to deliver visible results. The SHIR™ Beauty & science products that are approved for marketing in the Europe are: SHIR CBD+ ANTI-AGING Beauty Sleeping Mask ,SHIR CBD MUST Eye Serum, SHIR CBD MUST Recovery Lotion, SHIR CBD MUST Glow Oil, SHIR CBD MUST Face Cream, SHIR CBD+ ANTI-AGING Facial Serum.
Innocan’s SHIR™ Beauty & Science CBD Derma Cosmetics
To view an enhanced version of this graphic, please visit:
“As a Pharma Company, Innocan is committed to creating premium products that meet the highest quality standards to provide consumer confidence,” Iris Bincovich, co-founder and CEO of Innocan states. “Compliance with EU regulation is a major milestone for us, following the receipt of technical validation from the FDA for the marketing in the US of our over-the-counter Relief & Go Pain Relief spray, a few weeks ago. The next step is to initiate our various distribution platforms to deliver our SHIR™ CBD Derma Cosmetic line across the European Union and other markets where legally permitted to do so.”
The Company, through its wholly owned subsidiary, Innocan Pharma Ltd., is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 Corona Virus using CBD. CBD-Loaded Exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
The Company signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The Company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The Company is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, the effectiveness and safety of the Company’s products, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61225
This Is Why Investors Are Pouring into the Plant-Based Market
The plant-based boom shows no signs of slowing
Houston, Texas–(Newsfile Corp. – September 25, 2020) – That’s especially true with a growing number of health-conscious consumers. With that base, analysts at Meticulous Research say the plant-based food market could be worth $74.2 billion by 2027, growing at a CAGR of 11.9%.
“The growth in this market is mainly attributed to the increasing incidence of intolerance for animal proteins, nutritional benefits offered by plant-based food, increasing vegan population, and venture investments in plant-based food.”
However, it’s not just food being disrupted by a shift to plant-based products.
It’s transforming the health and wellness market, too.
The global vegan cosmetics market could be worth up to $20.8 billion over the next five years, according to Grand View Research. All on the belief that plant-based products are far better for their health, consumers are pushing for natural alternatives.
Better still, health conscious consumers are shifting to cold-pressed juice.
That the market alone could grow by $275.5 million between 2019 and 2023, according to analysts at Technavio. In addition, “Cold-pressed juice is extremely popular, as it contains nutrients known to boost immunity and general health, but it’s not something that a lot of consumers feel comfortable making at home due to the cleanup, time, and expertise required to get the right taste,” said Penny White, CEO of Better Plant Sciences.
Better Plant Sciences (CSE: PLNT) (OTCQB: VEGGF) is a Driving Force
For one the company just announced that its JUSU Bar juices are now available for online order in Victoria through www.jusubaryyj.com for home delivery.
JUSU Bar currently has one retail juice bar location open in Victoria, British Columbia, and is now delivering cold-pressed JUSU juices directly to customers through its eCommerce store. Better Plant has plans to continue expansion of the juice delivery program across Canada and the U.S. over the next year.
“Organic cold-pressed juice is the perfect fuel to help everyone look after their immune systems, and it has never been more important to do so,” said JUSU Founder, Bruce Mullen. “We have no-contact delivery and pickup available to keep our customers safe.”
Two, Better Plant Sciences just signed an eCommerce lease agreement on August 31, 2020 to take over the day-to-day sales of all Jusu Life and Jusu Body products. The eCommerce lease agreement, along with an inventory purchase, will allow Better Plant to book revenues from all eCommerce and wholesale sales of over 200 JUSU plant-based products for body, baby and home as of September 1, 2020.
“Since the 2017 acquisition of a large plant-based formula library, to the recently announced agreement to acquire JUSU Bar and all JUSU plant-based products, this aligns with our plans to build out our plant-based catalogue and sales,” says CEO Penny White.
And three, Better Plant Sciences just submitted a Natural Health Product application for Ayurveda skin ointment to help combat infectious diseases to Health Canada.
For more information, visit the company’s website at https://betterplantsciences.com
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Better Plant Sciences Inc., Winning Media has been paid two thousand dollars for advertising and marketing services for Better Plant Sciences Inc. We own ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64647
Vitalis places No. 3 on The Globe and Mail’s second-annual ranking of Canada’s Top Growing Companies
KELOWNA, British Columbia, Sept. 25, 2020 (GLOBE NEWSWIRE) — Vitalis Extraction Technology, Inc. (Vitalis) is pleased to announce it has placed No. 3 on the Globe and Mail’s 2020 Report on Business ranking of Canada’s Top Growing Companies.
Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Vitalis earned its spot with a three-year growth of 8,090 per cent.
Vitalis is a world-class manufacturer of industrial-scale supercritical CO2 extraction systems for a broad range of industries, turning their organic materials into pure extracts. Vitalis builds for the future and continues to raise the bar for safety, service and performance to serve its diverse customer base that includes producers of cannabis, hemp, pharmaceuticals, F&B and essential oils.
“What an honour it is to be recognized on this list of great Canadian companies. It is truly a testament to our team and technological innovations, coupled with the trust of our industry-leading clients that has fueled our global growth from our proudly Canadian roots,” said Joel Sherlock, co-founder and chairman of Vitalis. “Vitalis was born on the premise of partnership – we believe that combining a customer-first approach with industry-leading innovation helps drive our clients’ success, which in turn propels our own business. This belief drove our decision to build components in-house, from the initial fabrication of raw steel and customized control systems to live on-site installation and training. We stand firmly behind the quality of every system. We’re proud to reach this milestone as we approach our 5th birthday, and excited to maintain this momentum of growth moving forward with our sights set on new products and new markets.”
Launched in 2019, the Canada’s Top Growing Companies editorial ranking aims to celebrate entrepreneurial achievement in Canada by identifying and amplifying the success of growth-minded, independent businesses in Canada. It is a voluntary program; companies had to complete an in-depth application process in order to qualify. In total, 400 companies earned a spot on this year’s ranking.
“The stories of Canada’s Top Growing Companies are worth telling at any time but are especially relevant in the wake of COVID-19 pandemic,” says James Cowan, Editor of Report on Business magazine. “As businesses work to rebuild the economy, their resilience and innovation make for essential reading.”
“Any business leader seeking inspiration should look no further than the 400 businesses on this year’s Report on Business ranking of Canada’s Top Growing Companies,” says Phillip Crawley, Publisher and CEO of The Globe and Mail. “Their growth helps to make Canada a better place, and we are proud to bring their stories to our readers.”
About The Globe and Mail
The Globe and Mail is Canada’s foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 5.9 million readers every week in print or digital formats, and Report on Business magazine reaches 2.1 million readers in print and digital every issue. The Globe and Mail’s investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.
Vitalis Extraction Technology Inc. (Vitalis) is a privately-owned, Kelowna BC -based engineering and manufacturing company, producing industrial supercritical CO2 extraction systems for the cannabis, hemp, pharmaceuticals, F&B and essential oil industries. The company’s core focus on innovation and design has vaulted it to the forefront of the market. Renowned for their reliability, scalability, and continuous operation, Vitalis systems are euGMP-compliant and carry the latest certifications, including the American Society of Mechanical Engineers (ASME), National Board (NB), Canadian Standard Association (CSA/CRN), and European Conformity (CE/PED). Vitalis is one of only a few Original Equipment Manufacturers in the space, with operations in Canada, Australia, USA, Columbia, Denmark, United Kingdom, and Serbia as well as in-country support centers spread across the globe. Visit https://vitaliset.com for more information.
For media inquiries, please contact:
Brookline Public Relations, Inc.
Red Light Holland’s iMicrodose Packs Are Now Available For Purchase In Stores and Online In The Netherlands Plus Launch Event and Global Livestream Update
Toronto, Ontario–(Newsfile Corp. – September 25, 2020) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation positioning itself to engage in the production, growth and sale of its brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce their iMicrodose Packs (“iMicrodose Packs“) powered by Red Light Holland are now available in stores and online for purchase in the Netherlands. Red Light Holland would also like to update the time for their launch event of iMicrodose (the “iMicrodose Launch Event“), Microdosing Packs, in the Netherlands from 5-8pm (CEST) today (Friday, September 25th, 2020) with a global livestream starting at approximately 6:30pm and ending around 7:00pm (CEST) / 12:30-1:00pm (EST). The Global Livestream will be made available at: glsr.live/iMicrodose and/or www.RedLightTruffles.com
“We are so proud. Our small team, including our President Hans Derix, have all worked extremely hard to get us to this momentous day for the company. Seriously, this is truly a magical day. On May 28th, I went on record saying Red Light Holland would aim to have product on shelves by the end of Q3, 2020. We have delivered and achieved that goal,” said Todd Shapiro, Chief Executive Officer and Director of the Company. “Today, from 5-8pm (CEST) at our iMicrodose Launch Event we will celebrate this first big win, but we recognize it’s just an initial step in our overall business plan and ultimate growth strategy in both building a responsible use recreational brand while continuing to develop our Science and Innovation division.”
Pictured: iMicrodose Packs powered by Red Light Holland
To view an enhanced version of this graphic, please visit:
Red Light Holland’s iMicrodose Packs are now available for purchase in The Netherlands (18+) at www.iMicrodose.nl and currently at the following locations: (i) two Tatanka locations (ii) the Headshop and (iii) plus Tatanka’s website at www.tatanka.nl
Update: The iMicrodose Launch Event time has been updated and will be held today Friday, September 25th, 2020, in Amsterdam at the A’DAM the Loft from 5-8 p.m (CEST) for press, artists, thought-leaders, successful entrepreneurs, local celebrities, and social media influencers. The event will feature a global live stream presentation at approximately 6:30pm (CEST) by CEO Todd Shapiro, as well as President Hans Derix and will feature local live artists and DJs including Manuel Broekman, Geza Weisz, Loes van Delft, Amanda van Effrink, aka #GLITZIEGAL and Daan Noppen.
About Red Light Holland Corp.
The Company is an Ontario-based corporation positioning itself to engage in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal, recreational market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.
For additional information on the Company:
Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control.
Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward- looking statements contained herein include, but are not limited to, information the timing and other aspects of the iMicrodose Launch Event, including anticipated guests. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward- looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. In particular, there is no guarantee that iMicrodose Launch Event will occur on September 25, 2020, or at all. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
Not for distribution to United States newswire services or for dissemination in the United States.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64632
Cannabis4 weeks ago
3 Rivers Biotech to Establish Genetic Fingerprinting and Pathogen Testing Lab
Cannabis3 weeks ago
Rapid Screening Tests Are Still Struggling to Keep up with Demand
Cannabis4 weeks ago
DGDM’s Disruptive Pesticide Product Targeted to MJ Growers Passes Testing Trials During Pre-EPA Certification Period
Cannabis2 weeks ago
DGDM Provides Further Analysis of Specific Trial Testing Results of Its Disruptive Pesticide Product Targeted at MJ Growers
Cannabis1 week ago
Sixth Wave Innovations Announces Collaborative “Green” Test Initiatives with Mining and Process Solutions (Australia)
Cannabis3 weeks ago
Fernhill Beverage Branches Out for Success!
Cannabis3 weeks ago
MediPharm Labs Enters Growing Latin American Medical Cannabis Market; Enters Supply Agreement With Cann Farm Peru
Cannabis2 weeks ago
Monument Health Chooses Nuance Dragon Ambient eXperience to Transform Physician-Patient Encounters with Ambient Clinical Intelligence